22 October 2021
Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
13 October 2021
PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of neuromuscular neurologist John W. Day, M.D., PhD, to its Scientific Advisory Board. Dr Day is a Professor of Neurology, Pediatrics (Genetics) and Pathology and Director of the Division of Neuromuscular Medicine at Stanford University.
1 September 2021
The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
31 August 2021
Heidi Henson will join PepGen’s Board of Directors. The company also announced the promotion of Jane Larkindale, PhD, to Vice President of Clinical Science.
18 August 2021
Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.
PepGen Announces Closing of $112.5M Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
5 August 2021
Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
23 July 2021
After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
25 June 2021
MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
18 June 2021
The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
11 June 2021
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
9 June 2021
PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.
7 June 2021
Dr Niels Svenstrup, PhD, will serve as Senior Vice President of Chemistry, Manufacturing & Controls. David Pelissier, CPA, will serve as Vice President of Finance. The new leaders will support PepGen in establishing its US presence, building its financial strategy and advancing its pipeline.
1 June 2021
MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
Nucleome Therapeutics Announces Appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board
25 May 2021
Nucleome’s unique technology platform has the potential to discover precision therapeutics across all therapy areas, with an initial focus on autoimmune diseases.
18 May 2021
HRH The Earl of Wessex speaks with Oxfordshire entrepreneurs, including Atherton Mutombwera, CEO of Hutano Diagnostics.
30 April 2021
Alchemab Therapeutics, the antibody therapeutic start-up backed by SV Health Investors, has graduated from the BioEscalator after 18 months in the Innovation Labs.
27 April 2021
MoA Technology, a spin-out company from Oxford University’s Department of Plant Sciences, has secured an additional £5M funding for its series A round to support the expansion and acceleration of its discovery programme.
16 April 2021
The biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
12 March 2021
MoA Technology has a new CEO, Dr Virginia Corless, an experienced leader of cutting-edge enterprises that aim to make agriculture more efficient and sustainable.
26 February 2021
BioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.